Sign in
Taking peoplePhase 3

Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France28 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
628 people, planned
Started
19 Oct 2023
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • cotrimoxazole
  • standard antibiotic therapy
Record updated
20 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Adult patients hospitalized in an ICU
  • Under mechanical ventilation for at least five days
  • Microbiologically confirmed VAP preferably on a distal lung sample (bronchoalveolar lavage or protected distal specimen) otherwise endotracheal aspiration
  • Enterobacteriaceae susceptible to cotrimoxazole, and for polymicrobial VAP, all bacteria susceptible to cotrimoxazole
  • 5) Treated for at least 24 hours by an appropriate empiric antibiotic therapy (at least one effective antibiotic from the initiation of treatment for this VAP episode), and for polymicrobial VAP, all bacteria susceptible to empiric antibiotic therapy
  • Stability of haemodynamic (stability or decrease in catecholamine dose) and respiratory (stability or improvement of FIO2) parameters

Who cannot take part

  • Patients previously included in the study
  • Infection requiring prolonged antibiotic-therapy (pleural empyema, lung abscess, necrotizing pneumonia, etc…)
  • Cardiac arrest without awakening
  • Contra-indication to cotrimoxazole:; allergy,; advanced liver insufficiency,; renal dysfunction with clearance <15 mL/min/1.73 m² without hemodialysis; G6PD deficiency; history of hypersensitivity to one of the components (in particular, hypersensitivity to sulphonamides; known macrocytic anemia defined by VGM >; treatment with methotrexate
  • Immunosuppression (neutropenia, HIV with CD4 lymphocytes below 200/mm3, immunosuppressive therapy or corticosteroid therapy >0.5 mg/kg/j before ICU admission)
  • Haemodynamic instability (increasing dose of a catecholamine in the last 24 hours)
  • Cystic fibrosis
  • Moribund state (patient likely to die within 24h)
  • Limitation of life support (comfort care applied only) at the time of screening
  • Enrolment to another interventional study on VAP care/management
  • Pregnancy or breastfeeding
  • Subject deprived of freedom, subject under a legal protective measure
  • No affiliation to any health insurance system
  • Refusal to participate to the study (patient or legal representative or family member or close relative if present)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Efficacy of cotrimoxazole as a de-escalation treatment for adult patients Ventilator-Associated Pneumonia in intensive care unit Multicentre randomized non-inferiority trial comparing cotrimoxazole to standard antibiotic therapy for enterobacterial VAP

The 2 groups in the trial

  • cotrimoxazoleTreatment being tested

    Use of cotrimoxazole for enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.

  • standard antibiotic therapyExisting treatment, for comparison

    Use of standard antibiotic therapy enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit. Multicentric Non-inferiority Randomised Controlled Trial
Record updated
20 May 2025